VCYT insider reports two stock sales with weighted avg prices

Rhea-AI Filing Summary

Veracyte (VCYT) insider activity: The company’s VP and Chief Accounting Officer reported open‑market sales of common stock. On 11/07/2025, 5,818 shares were sold at a weighted average price of $40.2078. On 11/10/2025, 5,102 shares were sold at a weighted average price of $42.3321. Following these transactions, beneficial ownership stood at 38,745 shares.

The filing notes that each weighted average reflects multiple trades within disclosed price ranges, with detailed breakdowns available upon request.

Insights

Governance & Insider Trading Analyst

Routine insider sales disclosed; neutral signal.

An executive officer of Veracyte reported two market sales of common stock with weighted average prices and post‑transaction holdings. Such Form 4 disclosures document changes in ownership and provide price context via stated ranges.

The transactions are typical administrative reporting and don’t, by themselves, indicate a shift in company fundamentals. The price ranges were $40.06–$40.958 and $42.2866–$42.4436, reflecting multiple executions aggregated into weighted averages.

Without additional context such as company performance or guidance, these insider sales are best viewed as neutral. Future ownership updates will appear in subsequent Forms 4 as applicable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wygant Jonathan

(Last) (First) (Middle)

6000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/07/2025		S		5,818	D	$40.2078(1)	43,847	D
Common Stock	11/10/2025		S		5,102	D	$42.3321(2)	38,745	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents weighted average sales price. Sale prices for the transactions range from $40.06 to $40.958. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

2. Represents weighted average sales price. Sale prices for the transactions range from $42.2866 to $42.4436. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Veracyte (VCYT) report?

An executive officer reported selling 5,818 shares on 11/07/2025 and 5,102 shares on 11/10/2025, both as open‑market sales at weighted average prices.

What were the weighted average sale prices in the Veracyte Form 4?

The weighted average sale prices were $40.2078 on 11/07/2025 and $42.3321 on 11/10/2025, each reflecting multiple trades.

What price ranges did the Form 4 disclose for the sales?

The filing lists ranges of $40.06–$40.958 for 11/07/2025 and $42.2866–$42.4436 for 11/10/2025.

How many Veracyte shares does the reporting person hold after the transactions?

Beneficial ownership after the reported transactions is 38,745 shares.

What is the reporting person’s role at Veracyte (VCYT)?

The reporting person is an officer, serving as VP and Chief Accounting Officer.

Was a Rule 10b5-1 trading plan indicated?

The form contains a standard checkbox reference to Rule 10b5-1, but the excerpt does not indicate it was checked.